Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

Sagard, J, Olofsson, T, Mogard, E, Marsal, J, Andréasson, K, Geijer, M, Kristensen, LE, Lindqvist, E & Wallman, JK 2022, 'Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis', Arthritis Research & Therapy, bind 24, nr. 1, 42, s. 42. https://doi.org/10.1186/s13075-022-02733-w

APA

Sagard, J., Olofsson, T., Mogard, E., Marsal, J., Andréasson, K., Geijer, M., Kristensen, L. E., Lindqvist, E., & Wallman, J. K. (2022). Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. Arthritis Research & Therapy, 24(1), 42. [42]. https://doi.org/10.1186/s13075-022-02733-w

CBE

MLA

Vancouver

Author

Sagard, Jonas ; Olofsson, Tor ; Mogard, Elisabeth ; Marsal, Jan ; Andréasson, Kristofer ; Geijer, Mats ; Kristensen, Lars Erik ; Lindqvist, Elisabet ; Wallman, Johan K. / Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. I: Arthritis Research & Therapy. 2022 ; Bind 24, Nr. 1. s. 42.

Bibtex

@article{fba2dddf16d9439990177578bf36536c,
title = "Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis",
abstract = "BACKGROUND: Based on clinical and genetic associations, axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) are suspected to have a linked pathogenesis. Gut dysbiosis, intrinsic to IBD, has also been observed in axSpA. It is, however, not established to what degree gut dysbiosis is associated with axSpA disease severity. The objective of this study was to compare gut dysbiosis frequency between controls, non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) patients and investigate whether gut dysbiosis is cross-sectionally associated with axSpA disease activity, physical function, mobility, or pain.METHODS: Gut dysbiosis was assessed by 16SrRNA analysis of feces from 44/88 nr-axSpA/AS patients (ASAS/mNY criteria) without inflammatory bowel disease (IBD) and 46 controls without IBD or rheumatic disease. The GA-map{\texttrademark} Dysbiosis Test was used, grading gut microbiota aberrations on a 1-5 scale, where ≥3 denotes dysbiosis. Proportions with dysbiosis were compared between the groups. Furthermore, standard axSpA measures of disease activity, function, mobility, and pain were compared between patients (nr-axSpA and AS combined) with and without dysbiosis, univariately, and adjusted for relevant confounders (ANCOVA).RESULTS: Gut dysbiosis was more frequent in AS than controls (36% versus 17%, p=0.023), while nr-axSpA (25% dysbiosis) did not differ significantly from either AS or controls. Univariately, most axSpA measures were significantly worse in patients with dysbiosis versus those without: ASDAS-CRP between-group difference 0.6 (95% CI 0.2-0.9); BASDAI 1.6 (0.8-2.4); evaluator's global disease activity assessment (Likert scale 0-4) 0.3 (0.1-0.5), BASFI 1.5 (0.6-2.4), and VAS pain (cm) 1.3 (0.4-2.2). Differences remained significant after adjustment for demographics, lifestyle factors, treatments, gut inflammation (fecal calprotectin ≥50 mg/kg), and gut symptoms, except for VAS pain. BASMI and CRP were not associated with dysbiosis.CONCLUSION: Gut dysbiosis, more frequent in AS patients than controls, is associated with worse axSpA disease activity and physical function, seemingly irrespective of both gut inflammation and treatments. This provides further evidence for an important link between disturbances in gastrointestinal homeostasis and axSpA.",
author = "Jonas Sagard and Tor Olofsson and Elisabeth Mogard and Jan Marsal and Kristofer Andr{\'e}asson and Mats Geijer and Kristensen, {Lars Erik} and Elisabet Lindqvist and Wallman, {Johan K}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = feb,
day = "12",
doi = "10.1186/s13075-022-02733-w",
language = "English",
volume = "24",
pages = "42",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis

AU - Sagard, Jonas

AU - Olofsson, Tor

AU - Mogard, Elisabeth

AU - Marsal, Jan

AU - Andréasson, Kristofer

AU - Geijer, Mats

AU - Kristensen, Lars Erik

AU - Lindqvist, Elisabet

AU - Wallman, Johan K

N1 - © 2022. The Author(s).

PY - 2022/2/12

Y1 - 2022/2/12

N2 - BACKGROUND: Based on clinical and genetic associations, axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) are suspected to have a linked pathogenesis. Gut dysbiosis, intrinsic to IBD, has also been observed in axSpA. It is, however, not established to what degree gut dysbiosis is associated with axSpA disease severity. The objective of this study was to compare gut dysbiosis frequency between controls, non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) patients and investigate whether gut dysbiosis is cross-sectionally associated with axSpA disease activity, physical function, mobility, or pain.METHODS: Gut dysbiosis was assessed by 16SrRNA analysis of feces from 44/88 nr-axSpA/AS patients (ASAS/mNY criteria) without inflammatory bowel disease (IBD) and 46 controls without IBD or rheumatic disease. The GA-map™ Dysbiosis Test was used, grading gut microbiota aberrations on a 1-5 scale, where ≥3 denotes dysbiosis. Proportions with dysbiosis were compared between the groups. Furthermore, standard axSpA measures of disease activity, function, mobility, and pain were compared between patients (nr-axSpA and AS combined) with and without dysbiosis, univariately, and adjusted for relevant confounders (ANCOVA).RESULTS: Gut dysbiosis was more frequent in AS than controls (36% versus 17%, p=0.023), while nr-axSpA (25% dysbiosis) did not differ significantly from either AS or controls. Univariately, most axSpA measures were significantly worse in patients with dysbiosis versus those without: ASDAS-CRP between-group difference 0.6 (95% CI 0.2-0.9); BASDAI 1.6 (0.8-2.4); evaluator's global disease activity assessment (Likert scale 0-4) 0.3 (0.1-0.5), BASFI 1.5 (0.6-2.4), and VAS pain (cm) 1.3 (0.4-2.2). Differences remained significant after adjustment for demographics, lifestyle factors, treatments, gut inflammation (fecal calprotectin ≥50 mg/kg), and gut symptoms, except for VAS pain. BASMI and CRP were not associated with dysbiosis.CONCLUSION: Gut dysbiosis, more frequent in AS patients than controls, is associated with worse axSpA disease activity and physical function, seemingly irrespective of both gut inflammation and treatments. This provides further evidence for an important link between disturbances in gastrointestinal homeostasis and axSpA.

AB - BACKGROUND: Based on clinical and genetic associations, axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) are suspected to have a linked pathogenesis. Gut dysbiosis, intrinsic to IBD, has also been observed in axSpA. It is, however, not established to what degree gut dysbiosis is associated with axSpA disease severity. The objective of this study was to compare gut dysbiosis frequency between controls, non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) patients and investigate whether gut dysbiosis is cross-sectionally associated with axSpA disease activity, physical function, mobility, or pain.METHODS: Gut dysbiosis was assessed by 16SrRNA analysis of feces from 44/88 nr-axSpA/AS patients (ASAS/mNY criteria) without inflammatory bowel disease (IBD) and 46 controls without IBD or rheumatic disease. The GA-map™ Dysbiosis Test was used, grading gut microbiota aberrations on a 1-5 scale, where ≥3 denotes dysbiosis. Proportions with dysbiosis were compared between the groups. Furthermore, standard axSpA measures of disease activity, function, mobility, and pain were compared between patients (nr-axSpA and AS combined) with and without dysbiosis, univariately, and adjusted for relevant confounders (ANCOVA).RESULTS: Gut dysbiosis was more frequent in AS than controls (36% versus 17%, p=0.023), while nr-axSpA (25% dysbiosis) did not differ significantly from either AS or controls. Univariately, most axSpA measures were significantly worse in patients with dysbiosis versus those without: ASDAS-CRP between-group difference 0.6 (95% CI 0.2-0.9); BASDAI 1.6 (0.8-2.4); evaluator's global disease activity assessment (Likert scale 0-4) 0.3 (0.1-0.5), BASFI 1.5 (0.6-2.4), and VAS pain (cm) 1.3 (0.4-2.2). Differences remained significant after adjustment for demographics, lifestyle factors, treatments, gut inflammation (fecal calprotectin ≥50 mg/kg), and gut symptoms, except for VAS pain. BASMI and CRP were not associated with dysbiosis.CONCLUSION: Gut dysbiosis, more frequent in AS patients than controls, is associated with worse axSpA disease activity and physical function, seemingly irrespective of both gut inflammation and treatments. This provides further evidence for an important link between disturbances in gastrointestinal homeostasis and axSpA.

UR - http://www.scopus.com/inward/record.url?scp=85124614782&partnerID=8YFLogxK

U2 - 10.1186/s13075-022-02733-w

DO - 10.1186/s13075-022-02733-w

M3 - Journal article

C2 - 35151357

VL - 24

SP - 42

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 1

M1 - 42

ER -

ID: 74474256